(CHECK ONE):

oForm 10-K

oForm 20-F

oForm 11-K

xForm 10-Q

oForm N-SAR

For Period Ended:

  January 31, 2012

oTransition Report on Form 10-K

oTransition Report on Form 20-F

oTransition Report on Form 11-K

oTransition Report on Form 10-Q

oTransition Report on Form N-SAR

For the Transaction Period Ended:   

Advanced BioMedical Technologies, Inc.

Full Name of Registrant

Former Name if Applicable

350 Fifth Avenue, 59th Floor

Address of Principal Executive Office (Street and Number)

New York, NY 10118

City, State and Zip Code

x

(a)

The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

x

(b)

The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and

o

(c)

The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

SEC 1344 (03-05)

Persons who are to respond to the collection of information contained in this form are not required torespond unless the form displays a currently valid OMB control number.

(1)

Name and telephone number of person to contact in regard to this notification

 Wang Hui

(718)

766-7898

(Name)

(Area Code)

(Telephone Number)

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

xYes

oNo

(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

oYes

  xNo

If so, attach an explanation of the anticipated change, bothnarrativelyand quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

ADVANCED BIOMEDICAL TECHNOLOGIES, INC.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date

March 16, 2012

By

/ s/ Wang Hui

Wang Hui

     Chief Executive Officer

ATTENTION

INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT

CONSTITUTE FEDERAL CRIMINAL VIOLATIONS

(SEE 18 U.S.C. 1001)